Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Solitary Fibrous Tumor, Pleural | 1 | 2014 | 2 | 0.470 |
Why?
|
| Pleura | 1 | 2014 | 4 | 0.470 |
Why?
|
| Bronchoscopy | 2 | 2020 | 34 | 0.290 |
Why?
|
| Bronchial Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 466 | 0.180 |
Why?
|
| Lipoma | 1 | 2020 | 11 | 0.170 |
Why?
|
| Iliac Aneurysm | 1 | 2015 | 8 | 0.130 |
Why?
|
| Hematuria | 1 | 2015 | 10 | 0.130 |
Why?
|
| Iliac Artery | 1 | 2015 | 19 | 0.130 |
Why?
|
| Arteriovenous Malformations | 1 | 2015 | 16 | 0.130 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 9 | 0.120 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 54 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2015 | 118 | 0.120 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 7 | 0.120 |
Why?
|
| Image-Guided Biopsy | 1 | 2014 | 20 | 0.120 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 126 | 0.110 |
Why?
|
| Lung | 1 | 2015 | 363 | 0.100 |
Why?
|
| Aged | 3 | 2020 | 5229 | 0.090 |
Why?
|
| Male | 4 | 2020 | 13041 | 0.070 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2006 | 12 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 19 | 0.060 |
Why?
|
| Humans | 7 | 2020 | 27165 | 0.060 |
Why?
|
| Disease Management | 2 | 2015 | 86 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 318 | 0.060 |
Why?
|
| Myelography | 1 | 2003 | 8 | 0.050 |
Why?
|
| Spinal Stenosis | 1 | 2003 | 15 | 0.050 |
Why?
|
| Spinal Cord Compression | 1 | 2003 | 20 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2003 | 58 | 0.050 |
Why?
|
| Cervical Vertebrae | 1 | 2003 | 113 | 0.050 |
Why?
|
| Middle Aged | 3 | 2020 | 6912 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 660 | 0.040 |
Why?
|
| Oklahoma | 2 | 2020 | 979 | 0.040 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1999 | 8 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 1999 | 31 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 812 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 1999 | 187 | 0.040 |
Why?
|
| Syndrome | 1 | 2015 | 78 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 1943 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2015 | 68 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2015 | 20 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 201 | 0.030 |
Why?
|
| Decompression, Surgical | 1 | 2015 | 73 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 369 | 0.030 |
Why?
|
| Female | 3 | 2020 | 14661 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2015 | 598 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 7506 | 0.020 |
Why?
|
| Gastroscopy | 1 | 2006 | 7 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2006 | 17 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 2006 | 16 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 47 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 41 | 0.020 |
Why?
|
| Rituximab | 1 | 2006 | 60 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 218 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 455 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 462 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 589 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 989 | 0.010 |
Why?
|
| Observer Variation | 1 | 2003 | 43 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 510 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 2285 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 67 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1999 | 119 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2003 | 2456 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 340 | 0.010 |
Why?
|